Home » Posts tagged with » Ad26.COV2.S
EC strikes deal for supply of JNJ-78436735 Covid-19 vaccine candidate

EC strikes deal for supply of JNJ-78436735 Covid-19 vaccine candidate

Johnson & Johnson (J&J) said that the European Commission (EC) has approved an advance purchase agreement for securing 200 million doses of the JNJ-78436735 Covid-19 vaccine candidate (Ad26.COV2.S) developed by its subsidiary Janssen Pharmaceutical Companies. Currently, the JNJ-78436735 vaccine candidate is being evaluated in the phase 3 ENSEMBLE Covid-19 vaccine trial across certain countries. The […]